{
  "as_of_date": "October 14, 2025",
  "programs": [
    {
      "asset": "AKEEGA (niraparib/abiraterone)",
      "indication": "M1 Metastatic Castration-Sensitive Prostate Cancer",
      "phase": null,
      "trial_or_program": "AMPLITUDE",
      "partner": "TESARO, an oncology-focused business within GSK",
      "notes": null
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Smoldering Multiple Myeloma",
      "phase": null,
      "trial_or_program": "AQUILA",
      "partner": "Genmab A/S",
      "notes": null
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Frontline multiple myeloma transplant ineligible",
      "phase": null,
      "trial_or_program": "CEPHEUS",
      "partner": "Genmab A/S",
      "notes": null
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)",
      "phase": null,
      "trial_or_program": "GLOW",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Mantle Cell Lymphoma",
      "phase": null,
      "trial_or_program": "Triangle",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer",
      "phase": null,
      "trial_or_program": "SunRISe-1",
      "partner": null,
      "notes": null
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Frontline Non Small Cell Lung Cancer in combination with chemotherapy",
      "phase": null,
      "trial_or_program": "PAPILLON",
      "partner": null,
      "notes": null
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": null,
      "phase": null,
      "trial_or_program": "PALOMA-3",
      "partner": null,
      "notes": "Subcutaneous"
    },
    {
      "asset": "Bleximenib",
      "indication": "Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine",
      "phase": null,
      "trial_or_program": "cAMeLot-2",
      "partner": null,
      "notes": null
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma TNI",
      "phase": null,
      "trial_or_program": "CARTITUDE-5",
      "partner": "Legend Biotech",
      "notes": null
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma Transplant Eligible vs ASCT",
      "phase": null,
      "trial_or_program": "CARTITUDE-6",
      "partner": "Legend Biotech",
      "notes": null
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "Localized Prostate Cancer",
      "phase": null,
      "trial_or_program": "ATLAS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "High Risk Prostate Cancer",
      "phase": null,
      "trial_or_program": "PROTEUS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer BCG-naïve High Risk",
      "phase": null,
      "trial_or_program": "SunRISe-3",
      "partner": null,
      "notes": null
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "High Risk Non Muscle Invasive Bladder Cancer BGC Experienced",
      "phase": null,
      "trial_or_program": "SunRISe-5",
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Head and Neck Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null
    },
    {
      "asset": "pasritamig",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer",
      "phase": null,
      "trial_or_program": "ORIGAMI-2",
      "partner": null,
      "notes": null
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer 2L",
      "phase": null,
      "trial_or_program": "ORIGAMI-3",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma A-CD38 Naïve",
      "phase": null,
      "trial_or_program": "MonumenTAL-3",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TAR-210 (RIS/erdafitinib)",
      "indication": "Intravesical Delivery System for Localized Bladder Cancer",
      "phase": null,
      "trial_or_program": "MoonRISe-1",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Multiple Myeloma 1-3PLs",
      "phase": null,
      "trial_or_program": "MajesTEC-3",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TE NDMM maintenance",
      "phase": null,
      "trial_or_program": "MajesTEC-4",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MajesTEC-9",
      "partner": null,
      "notes": null
    },
    {
      "asset": "Bleximenib",
      "indication": "Relapsed Refractory Acute Myeloid Leukemia",
      "phase": null,
      "trial_or_program": "ALE1001",
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-0683 (ARX788)",
      "indication": "Breast Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma",
      "phase": null,
      "trial_or_program": "RedirecTT-1",
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-0387",
      "indication": "Solid Tumors",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-0631 (ARX305)",
      "indication": "Renal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-1493",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-2638",
      "indication": "Gastrointestinal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-2761",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-3413",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4496",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4680",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4681",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4916",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-5322",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-6420",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-7446",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-8177 (ARX517)",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-8377",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-8543",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-9401",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-9530",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-9892",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-9968",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriasis",
      "phase": null,
      "trial_or_program": "ICONIC",
      "partner": null,
      "notes": null
    },
    {
      "asset": "SIMPONI (golimumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "PURSUIT 2",
      "partner": "Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation",
      "notes": null
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Crohn's Disease",
      "phase": null,
      "trial_or_program": "UNITI JR",
      "partner": null,
      "notes": null
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "UNIFI JR",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Juvenile Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": "MorphoSys AG",
      "notes": null
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Psoriasis",
      "phase": null,
      "trial_or_program": "PROTOSTAR",
      "partner": "MorphoSys AG",
      "notes": null
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Psoriatic Arthritis Structural Damage",
      "phase": null,
      "trial_or_program": "APEX",
      "partner": "MorphoSys AG",
      "notes": null
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Ulcerative Colitis Subcutaneous Induction",
      "phase": null,
      "trial_or_program": "ASTRO",
      "partner": "MorphoSys AG",
      "notes": null
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Warm Autoimmune Hemolytic Anemia",
      "phase": null,
      "trial_or_program": "ENERGY",
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Sjogren's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Hemolytic Disease of the Fetus and Newborn",
      "phase": null,
      "trial_or_program": "AZALEA",
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Fetal and Neonatal Alloimmune Thrombocytopenia",
      "phase": null,
      "trial_or_program": "FREESIA",
      "partner": null,
      "notes": null
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "QUASAR JR",
      "partner": "MorphoSys AG",
      "notes": null
    },
    {
      "asset": "icotrokinra",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Crohn's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-5939",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Systemic Lupus Erythematosus",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Idiopathic Inflammatory Myopathy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-5108",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-6848",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-7528",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Adjunctive Treatment for Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis",
      "phase": null,
      "trial_or_program": "Vivacity MG3",
      "partner": null,
      "notes": null
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis Pediatrics",
      "phase": null,
      "trial_or_program": "VIBRANCE MG",
      "partner": null,
      "notes": null
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Treatment Resistant Depression monotherapy",
      "phase": null,
      "trial_or_program": "TRD4005",
      "partner": null,
      "notes": null
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Bipolar Mania",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Pediatric Psychiatric Indications",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "nipocalimab",
      "indication": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "phase": null,
      "trial_or_program": "ARISE",
      "partner": null,
      "notes": null
    },
    {
      "asset": "RPGR Gene Therapy",
      "indication": "Retinitis Pigmentosa",
      "phase": null,
      "trial_or_program": "LUMEOS",
      "partner": "UCL Business Plc",
      "notes": "AAV-RPGR"
    },
    {
      "asset": "seltorexant",
      "indication": "Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms",
      "phase": null,
      "trial_or_program": "OARS",
      "partner": null,
      "notes": null
    },
    {
      "asset": "ITI-1284",
      "indication": "Generalized Anxiety Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Psychosis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Agitation",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "JNJ-1887 sCD59",
      "indication": "Geographic Atrophy",
      "phase": null,
      "trial_or_program": null,
      "partner": "Hemera Biosciences",
      "notes": null
    },
    {
      "asset": "JNJ-2056 (tau active immunotherapy)",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "RETAIN",
      "partner": "AC Immune SA",
      "notes": "AC Immune ACI-35.030"
    },
    {
      "asset": "JNJ-5120",
      "indication": "Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "posdinemab",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "AUTONOMY",
      "partner": null,
      "notes": null
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Major Depressive Disorder with Suicidal Ideation Pediatrics",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "CABENUVA",
      "indication": "HIV Adolescents",
      "phase": null,
      "trial_or_program": null,
      "partner": "ViiV Healthcare",
      "notes": null
    },
    {
      "asset": "UPTRAVI (selexipag)",
      "indication": "Pediatric Pulmonary Arterial Hypertension",
      "phase": null,
      "trial_or_program": "SALTO",
      "partner": "Nippon Shinyaku",
      "notes": null
    },
    {
      "asset": "macitentan",
      "indication": "Pulmonary Arterial Hypertension 75mg",
      "phase": null,
      "trial_or_program": "UNISUS",
      "partner": "Nippon Shinyaku",
      "notes": null
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Secondary Stroke Prevention",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Acute Coronary Syndrome",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Atrial Fibrillation",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null
    },
    {
      "asset": "SIRTURO",
      "indication": "Leprosy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    },
    {
      "asset": "SIRTURO",
      "indication": "Tuberculosis Long Acting",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null
    }
  ],
  "_meta": {
    "run_date_utc": "2026-01-08",
    "source_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf",
    "input_text_sha256": "c8346bd17a91794d9b776b0953bb625a6580b4ee8d53710ed2d456500a7a481d",
    "ocr_max_pages": 12,
    "ocr_dpi": 220,
    "source_type": "jnj_q4cdn_auto",
    "stored_pdf_path": "sources/jnj/2026-01-08.pdf",
    "source_sha256": "7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04",
    "doc_unchanged": true,
    "doc_unchanged_note": "Source PDF SHA256 unchanged; reused prior snapshot to avoid extraction variability.",
    "extraction_ok": true
  }
}